- Khiron and the Colombia Cancer League, together with 21 leading
medical institutions in 11 cities throughout Colombia, have co-launched the "Cannabis:
Medicine for Your Life" campaign which aims to improve safe access
to consultations for medical cannabis
- Physicians participating in the campaign will donate more than
3,000 consultations, initially available to chronic pain,
palliative care and oncology patients
- As the leading provider of medical cannabis in Colombia, Khiron has filled over 18,000
prescriptions to date, achieving more than 120% growth in medical
cannabis prescriptions filled between Q1/21 and Q4/20 with gross
margins of over 80%
TORONTO, May 25, 2021 /CNW/ - Khiron Life Sciences
Corp. ("Khiron" or the "Company") (TSXV: KHRN) (OTCQX:
KHRNF)(Frankfurt: A2JMZC), a
vertically integrated medical cannabis leader with core operations
in Latin America and Europe, today announces, in partnership with
the Colombia Cancer League, the launch of the "Cannabis: Medicine
for Your Life" campaign throughout Colombia. In partnership with the Colombia
Cancer League and 21 medical clinics throughout the country,
chronic pain, palliative care and oncology patients (seeking to
manage chemotherapy related sickness) will be able to access
consultations for medical cannabis.
Khiron Partners with Colombia Cancer League to Deliver 3,000
Medical Cannabis Patient Consultations
Alvaro Torres, CEO and Director
comments, "We are very excited to be partnering with some of the
country's leading specialized medical institutions to increase
awareness and provide safe access to patients seeking different
types of treatments. As more external health care providers
complete our medical cannabis education program, physician
engagement and willingness to prescribe continues to improve,
providing greater access to the more than two million patients that
suffer from chronic pain in Colombia. In due course, we hope to expand the
reach of these campaigns to include additional pathologies and more
countries throughout the region."
The campaign will be hosted in 11 Colombian cities in
partnership with 21 participating clinics, which will be donating
up to 3,000 medical consultations throughout the month of June.
Consultations will be provided both in person and through
teleconsultation channels. The campaign will be co-organized by
Khiron and the Colombia Cancer League, a leading institution in the
provision of oncology services, with 60 years of experience in the
country.
Patients may schedule their consultation by dialing +57 333
0333191 or through the website
www.cannabismedicinaparatuvida.com.
About Khiron Life Sciences Corp.
Khiron is a
vertically integrated medical and CPG cannabis company with core
operations in Latin America, and
operational activity in Europe and
North America. Khiron is the
leading medical cannabis provider in Colombia and the first company licensed in
Colombia for the cultivation,
production, domestic distribution and sales, and international
export of both low and high THC medical cannabis products. The
Company has filled medical cannabis prescriptions in Colombia, Peru, Germany
and the United Kingdom, and is
positioned to commence sales in Mexico and Brazil in 2021.
Leveraging wholly-owned medical clinics and proprietary
telemedicine platforms, Khiron combines a patient-oriented
approach, physician education programs, scientific expertise,
product innovation, and agricultural infrastructure to drive
prescriptions and brand loyalty. Its Wellbeing Products unit
launched the first branded CBD skincare brand in Colombia, with Kuida™ now marketed in multiple
jurisdictions in Latin America,
the US and United Kingdom. The
Company is led by Co-founder and Chief Executive Officer,
Alvaro Torres, together with an
experienced and diverse executive team and Board of Directors.
Visit Khiron online at investors.khiron.ca and on Instagram
@khironlife.
Cautionary Notes
Forward-Looking Statements
This press release may contain certain "forward-looking
information" and "forward-looking statements" within the meaning of
applicable securities legislation. All information contained herein
that is not historical in nature may constitute forward-looking
information. Khiron undertakes no obligation to comment on
analyses, expectations or statements made by third-parties in
respect of Khiron, its securities, or financial or operating
results (as applicable). Although Khiron believes that the
expectations reflected in forward-looking statements in this press
release are reasonable, such forward-looking statement has been
based on expectations, factors and assumptions concerning future
events which may prove to be inaccurate and are subject to numerous
risks and uncertainties, certain of which are beyond Khiron's
control, including the risk factors discussed in Khiron's Annual
Information Form which is available on Khiron's SEDAR profile at
www.sedar.com. The forward-looking information contained in this
press release is expressly qualified by this cautionary statement
and is made as of the date hereof. Khiron disclaims any intention
and has no obligation or responsibility, except as required by law,
to update or revise any forward-looking information, whether as a
result of new information, future events or otherwise.
Neither the TSXV nor its Regulation Services Provider (as that
term is defined in the policies of the TSXV) accepts responsibility
for the adequacy or accuracy of this press release.
Investor Contact:
Paola Ricardo
E: investors@khiron.ca
T: +1 (647) 556-5750
Media Contact:
Elsa
Navarro
VP Communications
E: dmartinez@khiron.ca
Khiron Europe:
Tejinder
Virk
Europe President
E: tvirk@khiron.ca
View original content to download
multimedia:http://www.prnewswire.com/news-releases/khiron-partners-with-colombia-cancer-league-to-deliver-3-000-medical-cannabis-patient-consultations-301298900.html
SOURCE Khiron Life Sciences Corp.